舒巴坦-度洛巴坦成功治疗碳青霉烯耐药鲍曼不动杆菌脑膜炎
本病例报告描述一名42岁女性碳青霉烯耐药鲍曼不动杆菌/醋酸钙不动杆菌复合体(CRAB)脑膜炎患者,尽管接受高剂量氨苄西林-舒巴坦和头孢地尔治疗,脑脊液培养持续阳性13天。第13天换用舒巴坦-度洛巴坦联合美罗培南后,后续4次脑脊液培养均为阴性,治疗14天后感染治愈。全基因组测序发现与头孢地尔敏感性降低相关的可能机制,并观察到肉汤微量稀释法中的矛盾效应。
要点
- CRAB脑膜炎经高剂量氨苄西林-舒巴坦和头孢地尔治疗13天脑脊液培养仍持续阳性。
- 换用舒巴坦-度洛巴坦联合美罗培南后4次脑脊液培养转阴,治疗14天感染治愈。
- 舒巴坦和度洛巴坦在脑脊液中可检测到,提示可穿透血脑屏障。
核心结论
- 本病例描述舒巴坦-度洛巴坦联合美罗培南成功治疗难治性CRAB脑膜炎,并强调需注意头孢地尔对CRAB分离株肉汤微量稀释法检测中可能观察到的矛盾效应。
研究设计与样本
- 病例报告:一名42岁女性CRAB脑膜炎患者,接受系列脑脊液培养、全基因组测序及舒巴坦-度洛巴坦输注前和输注开始后3小时的血和脑脊液样本采集。
主要发现
- 患者接受高剂量氨苄西林-舒巴坦和头孢地尔治疗期间,脑脊液培养持续阳性13天。
- 第13天换用舒巴坦-度洛巴坦联合美罗培南后,后续4次脑脊液培养均为阴性,舒巴坦-度洛巴坦治疗14天后感染治愈。
- CRAB分离株属于序列型2,携带获得性blaOXA-23和固有blaOXA-51样(即blaOXA-66)碳青霉烯酶基因。
- 头孢地尔暴露8天后肉汤微量稀释法观察到矛盾效应(低稀释度无生长而高稀释度生长),纸片扩散法未观察到。
- 头孢地尔耐药潜在标志包括piuA和piuC铁转运基因起始密码子突变及PBP3的A515V替换。
临床怎么用
- 作者报告舒巴坦-度洛巴坦联合美罗培南成功治疗难治性CRAB脑膜炎,并提醒注意头孢地尔肉汤微量稀释法检测CRAB分离株时可能出现的矛盾效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The treatment of carbapenem-resistant Acinetobacter baumannii/calcoaceticus complex (CRAB) presents significant treatment challenges. METHODS: We report the case of a 42-year-old woman with CRAB meningitis who experienced persistently positive cerebrospinal fluid (CSF) cultures for 13 days despite treatment with high-dose ampicillin-sulbactam and cefiderocol. On day 13, she was transitioned to sulbactam-durlobactam and meropenem; 4 subsequent CSF cultures remained negative. After 14 days of sulbactam-durlobactam, she was cured of infection. Whole genome sequencing investigations identified putative mechanisms that contributed to the reduced cefiderocol susceptibility observed during cefiderocol therapy. Blood and CSF samples were collected pre-dose and 3-hours post initiation of a sulbactam-durlobactam infusion. RESULTS: The CRAB isolate belonged to sequence type 2. An acquired blaOXA-23 and an intrinsic blaOXA-51-like (ie, blaOXA-66) carbapenemase gene were identified. The paradoxical effect (ie, no growth at lower cefiderocol dilutions but growth at higher dilutions) was observed by broth microdilution after 8 days of cefiderocol exposure but not by disk diffusion. Potential markers of resistance to cefiderocol included mutations in the start codon of piuA and piuC iron transport genes and an A515V substitution in PBP3, the primary target of cefiderocol. Sulbactam and durlobactam were detected in CSF at both timepoints, indicating CSF penetration. CONCLUSIONS: This case describes successful treatment of refractory CRAB meningitis with the administration of sulbactam-durlobactam and meropenem and highlights the need to be cognizant of the paradoxical effect that can be observed with broth microdilution testing of CRAB isolates with cefiderocol.
引用
- Tamma PD, Immel S, Karaba SM, et al. Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam. Clin Infect Dis. 2024. PMID: 38630890. doi:10.1093/cid/ciae210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。